Alto Neuroscience, Inc. (NYSE:ANRO) Shares Sold by Alkeon Capital Management LLC

Alkeon Capital Management LLC decreased its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 49.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 477,101 shares of the company's stock after selling 457,803 shares during the period. Alkeon Capital Management LLC owned 1.77% of Alto Neuroscience worth $2,018,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Almitas Capital LLC purchased a new position in Alto Neuroscience during the 4th quarter worth $1,129,000. Jane Street Group LLC raised its position in Alto Neuroscience by 72.0% during the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after buying an additional 7,783 shares during the last quarter. Northern Trust Corp lifted its position in Alto Neuroscience by 198.1% during the fourth quarter. Northern Trust Corp now owns 587,135 shares of the company's stock valued at $2,484,000 after purchasing an additional 390,190 shares during the period. Boothbay Fund Management LLC grew its position in Alto Neuroscience by 1,941.1% during the 4th quarter. Boothbay Fund Management LLC now owns 103,100 shares of the company's stock worth $436,000 after purchasing an additional 108,700 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Alto Neuroscience by 4.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 844,823 shares of the company's stock worth $3,575,000 after buying an additional 36,319 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ANRO shares. William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a report on Friday, March 21st. HC Wainwright started coverage on Alto Neuroscience in a research note on Monday, April 7th. They set a "buy" rating and a $10.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Trading Up 3.7 %

NYSE:ANRO traded up $0.08 during trading hours on Thursday, hitting $2.25. The company had a trading volume of 100,169 shares, compared to its average volume of 380,161. The company has a 50-day moving average of $2.52 and a 200 day moving average of $3.66. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The company has a market cap of $60.91 million, a P/E ratio of -0.89 and a beta of 1.87. Alto Neuroscience, Inc. has a 1 year low of $1.60 and a 1 year high of $17.55.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.09. Sell-side analysts expect that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.